PDA

View Full Version : Alnylam presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Sym


News
11-11-2010, 12:23 AM
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

More... (http://www.news-medical.net/news/20101111/Alnylam-presents-ALN-VSP-Phase-I-data-for-liver-cancer-at-Chemotherapy-Foundation-Symposium.aspx)